GUPEA >
Sahlgrenska Academy / Sahlgrenska akademin >
Institute of Clinical Sciences / Institutionen för kliniska vetenskaper >
Doctoral Theses / Doktorsavhandlingar Institutionen för kliniska vetenskaper >

New Prognostic Markers in Stage III Serous Ovarian Adenocarcinomas


Please use this identifier to cite or link to this item: http://hdl.handle.net/2077/10126

Files in This Item:

File Description SizeFormat
spikblad_Partheen.pdfAbstract104KbAdobe PDF
View/Open
sammanfattning_Partheen.pdfThesis frame807KbAdobe PDF
View/Open
Title: New Prognostic Markers in Stage III Serous Ovarian Adenocarcinomas
Authors: Partheen, Karolina
E-mail: karolina.partheen@gu.se
Issue Date: 15-May-2008
University: University of Gothenburg. Sahlgrenska Academy
Institution: Inst of Clincial Sciences. Dept of Oncology
Parts of work: I. Partheen, K., Levan K., Osterberg, L., Helou, K., Horvath, G. Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage. Genes Chromosomes Cancer, 2004;40(4):342-8.
VIEW ARTICLE


II. Partheen, K., Levan K., Osterberg, L., Horvath, G. Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. European Journal of Cancer, 2006;42(16):2846-54
VIEW ARTICLE


III. Partheen, K., Levan K., Osterberg, L, Claesson I., Fallenius G., Sundfeldt K., Horvath G. Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. Conditionally accepted in International Journal of Cancer

IV. Partheen, K., Levan K., Osterberg, L, Claesson I., Sundfeldt K., Horvath G. External validation suggests Integrin Beta 3 (ITGB3) as prognostic biomarker in serous ovarian adenocarcinomas. Manuscript
Disputation: Torsdagen den 5 juni 2008, kl. 9.00, i hörsal Arvid Carlsson, Medicinaregatan 3, Göteborg
Degree: Doctor of Philosophy (Medicine)
Publication type: Doctoral thesis
Keywords: Ovarian cancer
Biomarker
Prognostic factors
Integrin beta 3
Abstract: Ovarian carcinoma is the fifth most common cause of cancer death in Swedish women. Patients with advanced-stage disease respond differently to treatment, and the clinical outcome is difficult to predict for an individual patient. To increase the knowledge about ovarian adenocarcinomas, we aimed to investigate genetic changes relevant to the growth and progression of advanced ovarian tumours. We classified the tumours on a biological basis to identify potential biomarkers for use as prognostic fa... more
ISBN: 978-91-628-7485-8
URI: http://hdl.handle.net/2077/10126
Appears in Collections:Doctoral Theses from Sahlgrenska Academy
Doctoral Theses / Doktorsavhandlingar Institutionen för kliniska vetenskaper
Doctoral Theses from University of Gothenburg / Doktorsavhandlingar från Göteborgs universitet

 

 

© Göteborgs universitet 2011